If any dietary supplement manufacturers are reading this, 3rd party lab testing adds only 1% to production costs and days to lead time. If softgels/capsules . CBD products by Green roads contains certified lab sheets that provide a brief on CBD dosage & ingredients Green Roads CBD Third Party Lab Test Results. Select the product category below to see the latest third party lab results for your product. If you can't find the lab results for the product you are looking for please.
Party Results 10) Third Lab
However, in terms of the cannabis industry, federal regulation has always been a bit of a double-edged sword. But on the other hand, quality manufacturers know that an industry without rules and regulations will quickly become overrun with scams, false advertising, and out-and-out lies — which makes it very hard for a consumer to make educated purchases, or receive quality, reliable information.
Of course, this is fine for all of the crooks and swindlers out there who simply want to cash in on the booming cannabis industry. Fortunately, this is where the beauty of transparency comes in: And most of them — nowadays at least — are accomplishing this through third party testing. They know that they are manufacturing and selling good, quality products, and they are not scared to have an unbiased, outside source verify it for them.
In all honesty, this is kind of a hazy subject. The straightforward, bottom line is that no, the Food and Drug Administration does not maintain any sort of regulation or oversight into the CBD industry. That being said, however, one of the inherent purposes of the FDA is to make sure that the general public is not being exposed to any dubious, dangerous, or questionable health products — including natural medications like cannabis.
Dozens of sub-par cannabis companies have found this out the hard way over the last several years. Like we just mentioned, it ultimately comes down to transparency.
Another reason why cannabis companies spend large amounts of money on laboratory testing is to obtain cannabinoid and terpene profiles for each of their various strains. And given the current unregulated state of the industry, this is an all too easy mistake to make. You would not believe the thousands upon thousands of people that get turned off to cannabis use, just because they used a crummy, low-quality product without knowing it.
Shop wisely, look for reliable, reputable brands with good consumer feedback, and never underestimate the importance of third-party quality tested products. Also, how often do these companies really lab test? Of course, the same cannot be said for all brands across the industry. Take some time and do some browsing around the companys sites. For example, serology data is important for vaccine trials. TPVL data processing involves many steps [ Figure 1 ].
All the process steps are very important in TPVL data because one step will affect all the other steps through a sequential or cascading effect. Selection of a TPVL is a cumbersome process and risks are very high because it involves biological samples for analysis. TPVL are selected based on the specific requirements of the clinical trial and sponsor expectation.
TPVL operates in different geographical locations and hence standard laboratory practices should be maintained in both central and local laboratories. Some key factors for selection of laboratory vendors for clinical trials include [ Figure 2 ]:.
TPVL management is very important for maintaining turn-around-time of deliverables, reasonable cost and good relationship to improve further in business. After selecting the TPVL through a request for proposal process, it is good to assess the requirements and specifications, risk, implementation planning and scheduling for data transfer. Once the clinical protocol is approved, sponsors engage in discussions with TPVL regarding the data transfer agreement DTA , file format specifications and data cleaning plan.
Implementing the procedures for collecting, transferring, loading and validating and editing external laboratory data document is crucial for clinical data management [ Figure 3 ]. Laboratory data is reconciled with site data during study conduct and any discrepancies are resolved with the laboratory vendor.
Best practices during study conduct include automation of checks for data and for reconciliation, streamlining query resolution process and implementation of issue trackers to track issues for future use to update standards and process. Finally, the third party data is placed in a central repository for further analysis. There are many reasons for slippage in third party data transfer to data management group DMG during the conduct and closeout phase of the study.
Other causes in delay are normal ranges for laboratory data, especially when local laboratories in use are not available, data entry issues and delays in responses to data queries, errors during data transfer and merger and discrepancies due to poor setup of database. Quality of deliverables should be continuously monitored using key performance indicators from study start up to closeout.
Poor quality in interpretation of results or missing the delivery schedule will affect the timelines of the study, which can cause late submission of clinical study report to regulatory authorities. Data managers are expected to look for the delay in processing the TPVL data address issues identified during reconciliation, communicate the timelines to the vendor and ensure common understanding between various stakeholders in order to ensure timely inclusion of laboratory data before database lock.
Efficient communication and good relationship with vendor can help in planning the schedules and steps to ensure timeliness of receipt of data. To this effect, the schedules, communication plan and roles and responsibilities should be discussed and agreed during the kick-off meeting.
Laboratory data should be reviewed in batches during the conduct of study so that generic issues can be identified and addressed during the course of study conduct. Best practices to avoid such situations are training, discussing improvement area or issues with the vendor, using reference documents, reconciliation checks and transfer of file according to the DTA, standard test names, quality assurance and quality control of laboratory data on the on-going basis and verification of reference ranges according to the local regulatory authorities.
TPVL can be monitored based on the commitment, performance and relationship. All the three components are interlinked to each other and breach in one area will affect other two.
Vendor performance should be monitored from signing the contract to database lock. Communication and escalation plan should be implemented based on the service level agreement and metrics. Gantt chart, resource plans and communication plans directly help in managing the vendors. Performing regular audits internally give significant information to the operational team to identify the areas of slippage, which can be corrected by training.
Corrective and preventive action should be reviewed to avoid such issues in the future. Regular assessments with the vendor identify weak and improvement areas, from sample processing to third party data transfer. Mitigation and escalation plan should be outlined in vendor oversight plan if timelines are expected to be deviated. TPVL management outlines the processes and framework for the data manager and the sponsor to measure the performance and improvement of collection of laboratory data that is analyzed and reported for evaluation of the outcome of the clinical trial.
In turn, the DMG should also acknowledge the advantage of this proactive approach for better quality, good relationship and future business. Good management of vendor will achieve a win-win situation for both DMG and the vendor. National Center for Biotechnology Information , U. Journal List Perspect Clin Res v. Jasmin Johnson , Vishwanath Kanagali , and D. Author information Copyright and License information Disclaimer.
Why are CBD Third-Party Lab Reports So Important?
testing, but every product also receives third-party lab clarification to ensure phytocannabinoid We make sure that testing identifies the amount of CBD, THC and other cannabinoid 10 mg. See Lab Results · lab Results Page Products. Test Results. In an effort to bring PURE SPECTRUM – Tincture mg & mg – (Batch ID: – 10/29/ · PURE SPECTRUM – Tincture mg . oil may be split into batches to make different products. Each individual product will then have its own CQA. Please click here to view third-party lab results.